Elicio Therapeutics Inc
NASDAQ:ELTX
Elicio Therapeutics Inc
NASDAQ:ELTX
Price:
11.79
USD
-8.6%
Market Closed
Market Cap:
$206.2m
Relative Value
The Relative Value of one
ELTX
stock under the Base Case scenario is
0.14
USD.
Compared to the current market price of 11.79 USD,
Elicio Therapeutics Inc
is
Overvalued by 99%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ELTX
Relative Value
Base Case
0.14
USD
Overvaluation 99%
Multiples Across Competitors
ELTX Competitors Multiples
Elicio Therapeutics Inc Competitors
Elicio Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Elicio Therapeutics Inc
NASDAQ:ELTX
|
203.5m USD | 0 | -4.4 | -4.5 | -4.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
944.6B USD | 14.5 | 45.8 | 30.9 | 32.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.1B USD | 6.2 | 21.8 | 15.2 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
255.3B CHF | 4.2 | 19.9 | 11.7 | 13.2 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.9B GBP | 5.1 | 29.5 | 16.3 | 23 | |
| CH |
|
Novartis AG
SIX:NOVN
|
232.7B CHF | 5.3 | 21.5 | 13.3 | 17.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
287.6B USD | 4.4 | 15.8 | 9.8 | 11.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.8 | 8 | 9.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.2B USD | 2.5 | 20 | 7.7 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120.7B USD | 2.5 | 17.1 | 7.2 | 8.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
